Partial
Mostly Aligned
Patient Risk:
Low
Summary
Indication-related claims are supported by the provided label sections, but multiple claims about patient assistance/discount programs and government coverage are not supported by the provided FDA label text.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglycerides.
1 INDICATIONS AND USAGE: adjunct to diet to reduce TG levels; also adjunct to maximally tolerated statin therapy to reduce TG in patients with elevated triglycerides.
Vascepa (icosapent ethyl) is used to reduce the risk of heart attacks in certain patients.
1 INDICATIONS AND USAGE: adjunct to maximally tolerated statin therapy to reduce risk of myocardial infarction in eligible adult patients.
Vascepa (icosapent ethyl) is used to reduce the risk of strokes in certain patients.
1 INDICATIONS AND USAGE: adjunct to maximally tolerated statin therapy to reduce risk of stroke in eligible adult patients.
Unsupported Statements
Amarin's Patient Assistance Program offers eligible patients Vascepa for free or at a reduced cost.
Not found in the provided label sections (1 INDICATIONS AND USAGE; 17 PATIENT COUNSELING INFORMATION).
Rx Outreach provides Vascepa at a discounted price for eligible low-income individuals.
Not found in the provided label sections.
Medicare Part D Low-Income Subsidy may provide assistance with the cost of Vascepa for eligible patients.
Not found in the provided label sections.
Medicaid may cover Vascepa prescriptions for eligible patients depending on the state.
Not found in the provided label sections.
Patients typically must meet certain income and eligibility criteria to qualify for patient assistance programs.
Not found in the provided label sections.
A healthcare provider can guide patients through the application process for patient assistance programs and government assistance programs for Vascepa.
Not found in the provided label sections.
A healthcare provider can help patients navigate complexities in the application process for Vascepa assistance programs.
Not found in the provided label sections.
A healthcare provider can provide support and advocacy throughout the process of securing financial aid for Vascepa.
Not found in the provided label sections.
Contradictions
Important Omissions
The provided extracted claims include no dosing/administration, contraindications, warnings/precautions, adverse reactions, or monitoring information to evaluate against the supplied label; however, the evaluation cannot confirm compliance in those areas because those label sections were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported financial assistance/coverage claims are not shown in the provided label text; while these may affect access or expectations, they are not directly tied to dosing/safety content in the provided label sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements about specific patient assistance/discount programs and government coverage are not supported by the provided FDA label sections.
Suggested Improvement
Limit claims to FDA-label-supported indications/usage and remove or generalize any non-label-supported information about specific assistance programs/discounts/coverage processes unless supported by the provided label text.